Seeking Alpha

More on Allergan (AGN) Q3: net profit almost flat at $249.4M. Specialty pharmaceuticals sales...

More on Allergan (AGN) Q3: net profit almost flat at $249.4M. Specialty pharmaceuticals sales +8.1%, medical devices -4%. Exploring options for obesity intervention business, including selling it. Guidance: Q4 EPS of $1.18-$1.20 vs consensus of $1.20, revenue of $1.47B-$1.545B vs $1.51B; FY EPS of $4.17-$4.19 vs $4.17 and revenue of $5.695B-$5.77B and $5.82B. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector